Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure
Authors:
- Sanchit SharmaSSSanchit Sharma
- Samagra AgarwalSASamagra Agarwal
- Anoop SarayaASAnoop Saraya
- Ashok Kumar ChoudhuryACAshok Kumar Choudhury
- Sanjiv SaigalSSSanjiv Saigal
- A. S. SoinASA. S. Soin
- Akash ShuklaASAkash Shukla
- Manoj K. SahuMSManoj K. Sahu
- Laurentius A. LesmanaLLLaurentius A. Lesmana
- Renaldi C. LesmanaRLRenaldi C. Lesmana
- Samir N. ShahSSSamir N. Shah
- Jinhua HuJHJinhua Hu
- 15 February 2023
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 989-999
Abstract
Background and aims Early identification of non-response to steroids is critical in patients with autoimmune hepatitis (AIH) causing acute-on-chronic liver failure (ACLF). We assessed if this non-response can be accurately identified within first few days of treatment. Methods Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [− 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks. Results Fifty-five out of one hundred and sixty-five patients (age—38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22–27); median AARC score 7 (6–9)] given oral prednisolone 40 (20–40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754–0.93)], MELD [0.837 (95% CI 0.733–0.94)] score and SURFASA score [0.795 (95% CI 0.678–0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687–0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ − 1.2, could identify non-responders at day 3 (concomitant— 75% vs either − 42%, p < 0.001). Conclusion Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.Keywords
This publication has 18 references indexed in Scilit:
- Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?Liver Transplantation, 2019
- Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid TherapyHepatology, 2019
- Prompt initiation of high‐dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitisHepatology Research, 2018
- Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide surveyJournal of Gastroenterology, 2018
- Severity and Outcome of Acute-on-Chronic Liver Failure is Dependent on the Etiology of Acute Hepatic InsultsJournal of Clinical Gastroenterology, 2017
- Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA modelsHepatology International, 2017
- Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcomeJournal of Hepatology, 2014
- Autoimmune acute liver failure: an emerging etiology for intractable acute liver failureHepatology International, 2012
- Autoimmune acute liver failure: Proposed clinical and histological criteriaHepatology, 2010
- Usefulness of Corticosteroids for the Treatment of Severe and Fulminant Forms of Autoimmune HepatitisLiver Transplantation, 2007